公司-财-016-2023-V3 上海医药集团股份有限公司 担保管理制度 第一章 总则 第一条 为规范上海医药集团股份有限公司（以下简称"公司"）对外担保行为， 防范担保风险，根据《中华人民共和国物权法》、《中华人民共和国担保法》、《中华人民 共和国民法典》（以下简称"《民法典》"）、中国证券监督管理委员会及证券交易所等监 管机构对于上市公司对外担保的相关规定、以及公司《章程》等规定，结合公司实际情 况，特制定本制度。 第二条 本制度规定的担保是指根据《中华人民共和国担保法》规定的以其信用出 具对外担保，或以《中华人民共和国担保法》规定的财产对外抵押，或以《中华人民共 和国担保法》、公司《章程》等规定的动产或权利对外质押，向债权人或受益人承诺， 当债务人未按照合同约定偿付债务时由担保人履行偿付义务的行为。具体类型包括一般 保证、连带责任保证、抵押、质押、具有担保效力的共同借款合同、差额补足承诺、安 慰承诺、维好协议等支持性函件等各种形式的担保。 第三条 本制度规定的担保业务范围包括公司为控股公司、控股公司之间、控股公 司为公司的融资行为提供的保证担保、抵押担保和质押担保及为其他日常经营活动提供 的保证担保；公 ...

上海医药集团股份有限公司 独立董事的独立意见 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》 （以下简称"《证券法》"）、《上海证券交易所股票上市规则》等相关法律法规和《上海医 药集团股份有限公司章程》（以下简称"《公司章程》"）的相关规定，我们作为上海医药集 团股份有限公司（以下简称"公司"）的独立董事，基于独立客观判断，就上海上实集团财务 有限公司2023年半年度风险持续评估报告发表独立意见如下： 经审阅公司出具的《上海医药集团股份有限公司关于上海上实集团财务有限公司2023半年 度风险持续评估报告》，我们认为财务公司风险持续评估报告具备客观性和公正性，财务公司 具备开展业务的相关资质，未发现财务公司风险管理存在重大缺陷。公司与财务公司相关交易 均在签署的《金融服务框架协议》范围内进行，风险可控，未发现财务公司存在影响公司资金 安全及资金调动的情形，不存在损害公司和全体股东尤其是中小股东利益的情形。 董事会审议相关议案时关联董事依法回避表决，董事会审议和表决程序符合《公司法》、 《证券法》等有关法律、法规以及《公司章程》的规定。我们同意上海上实集团财务有限公司 2023半 ...

1、《2023 年半年度报告及摘要》 内容详见上海证券交易所网站 www.sse.com.cn。 表决结果：赞成 9 票，反对 0 票，弃权 0 票 2、《上海上实集团财务有限公司 2023 半年度风险持续评估报告》 证券代码：601607 证券简称：上海医药 公告编号：临2023-070 上海医药集团股份有限公司 第八届董事会第三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 上海医药集团股份有限公司（以下简称"本公司"或"上海医药"）第八届董事 会第三次会议（以下简称"本次会议"）于 2023 年 8 月 29 日在上海市太仓路 200 号上海医药大厦以现场方式召开。本次会议应到董事九名，实到董事九名，符合 《中华人民共和国公司法》和本公司章程关于董事会召开法定人数的规定。本次 会议由周军董事长主持，监事和部分高级管理人员列席本次会议。 二、董事会会议审议情况 本次会议审议并通过了以下议案： 上海医药集团股份有限公司 董事会 二零二三年八月三十日 内容详见上海证券交易所网站 w ...

上海医药集团股份有限公司 关于上海上实集团财务有限公司 2023 半年度风险持续评估报 告 根据《上海证券交易所上市公司自律监管指引第 5 号——交易与关联交易》的 要求，上海医药集团股份有限公司（以下简称"上海医药"或"我们"）通过查验 上海上实集团财务有限公司（以下简称"财务公司"）的《金融许可证》、《营业 执照》等证件资料，审阅其二〇二三年度中期财务报表，对经营资质、业务和风险 状况进行了解和评估。具体情况报告如下： 一、 企业基本情况及经营资质 上海上实集团财务有限公司由上海上实（集团）有限公司（股东一）、上海医 药集团股份有限公司（股东二）、上海上实资产经营有限公司（股东三）以及上海 实业东滩投资开发（集团）有限公司（股东四）合资成立。2014 年 9 月 1 日在中华 人民共和国上海市注册成立的有限责任公司。 财务公司于 2014 年 8 月 26 日取得中国银行业监督管理委员会上海监管局的沪 银监复、[2014]561 号开业批复，于 2014 年 9 月 1 日成立，注册资本人民币 10 亿 元整，己于 2014 年 5 月 19 日全部缴入。财务公司取得上海市黄浦区市场监督管理 局颁发的 0 ...

证券代码：601607 证券简称：上海医药 公告编号：临 2023-069 上海医药集团股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （网址：https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 8 月 25 日(周五)至 8 月 29 日(周二)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目进行提问。公 司将在说明会上对投资者普遍关注的问题进行回答。 上海医药集团股份有限公司（以下简称"公司"）将于 2023 年 8 月 29 日发布公司 2023 年半年度报告，为便于广大投资者更全面深入 地了解公司 2023 年上半年经营成果、财务状况，公司计划于 2023 年 8 月 30 日下午 13:00-14:00 举行 2023 年半年度业绩说明会，就投资 者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2023 年上 半年的经 ...

证券代码：601607 证券简称：上海医药 编号：临2023-068 上海医药集团股份有限公司 关于盐酸美金刚片获得批准生产的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，上海医药集团股份有限公司（以下简称"上海医药"或"公司"）下 属控股子公司上海上药中西制药有限公司（以下简称"上药中西"）的盐酸美金 刚片（以下简称"该药品"）收到国家药品监督管理局（以下简称"国家药监局"） 颁发的《药品注册证书》（证书编号：2023S01232、2023S01233），该药品获得 批准生产。 一、该药品基本情况 药物名称：盐酸美金刚片 剂型：片剂 规格：10mg、20mg 二、 该药品相关的信息 盐酸美金刚片主要用于治疗中重度至重度阿尔茨海默型痴呆。最早由 Merz 公司研发。2002 年，该产品在欧盟批准上市。2021 年 3 月，上药中西就该药品 向国家药监局提出注册上市申请，并获受理。 截至本公告日，中国境内该药品的主要生产厂家包括珠海联邦制药股份有 限公司中山分公司、湖南洞庭药业股份有限公司、广州白云山医药集团 ...

Financial Performance - Shanghai Pharmaceuticals reported a revenue of RMB 100 billion for the fiscal year 2022, representing a year-on-year growth of 12%[11]. - The company achieved a net profit of RMB 8 billion, which is an increase of 15% compared to the previous year[11]. - Shanghai Pharmaceuticals achieved a revenue of RMB 231.98 billion in 2022, an increase of approximately 7.4% compared to RMB 215.82 billion in 2021[25]. - The company's pre-tax profit for 2022 was RMB 8.81 billion, reflecting a growth of about 8.2% from RMB 8.14 billion in 2021[25]. - The net profit attributable to shareholders was RMB 5.62 billion in 2022, representing a growth of around 10.3% from RMB 5.09 billion in 2021[25]. - The company reported a significant increase in sales costs, management expenses, and financial costs, with changes exceeding 30% year-on-year[93]. - The company reported a sales revenue increase of 7.49% compared to the previous year, reaching approximately ¥231.98 billion[88]. Research and Development - The company is investing RMB 1.5 billion in R&D for innovative drug development, aiming to introduce at least two first-in-class drugs by 2025[11]. - The company has increased its R&D investment by over RMB 2 billion compared to five years ago, indicating a strong commitment to innovation[28]. - Research and development investment totaled RMB 2.8 billion, marking an 11.87% increase compared to the previous year[34]. - The company has expanded its innovative drug pipeline from 16 to 50 projects since 2017, with two new drug applications recently submitted[34]. - The company is actively expanding its research and development efforts across various therapeutic areas, including oncology, autoimmune diseases, and metabolic disorders[49]. - The company has established partnerships with several universities and research institutions to enhance its innovative drug development capabilities[61]. - The company aims to enhance the quality and quantity of R&D outcomes by reforming its innovation mechanism and focusing on patient needs[110]. Market Expansion and Strategy - Shanghai Pharmaceuticals plans to launch three new products in the next fiscal year, targeting a market share increase of 5% in the pharmaceutical sector[11]. - Market expansion efforts include entering two new international markets, with projected revenue contributions of RMB 2 billion in the first year[11]. - The company is exploring strategic acquisitions to enhance its product portfolio, with a budget of RMB 3 billion allocated for potential mergers and acquisitions[11]. - Shanghai Pharma's internationalization strategy made significant progress with the establishment of subsidiaries in Thailand and a joint venture in Singapore, expanding its global business footprint[42]. - The company plans to establish 30 high-quality overseas Chinese medicine centers and develop 50 international cooperation bases to enhance its global presence[73]. - The company aims to enhance its market position by leveraging synergies across its pharmaceutical and retail segments, capitalizing on the continuous growth opportunities in China's healthcare sector[71]. Financial Health and Investments - Total assets reached RMB 198.13 billion in 2022, up from RMB 163.44 billion in 2021, marking an increase of approximately 21.2%[26]. - Total liabilities rose to RMB 120.13 billion in 2022, an increase of approximately 15.1% from RMB 104.37 billion in 2021[26]. - The company has a robust financial structure with a well-controlled debt-to-asset ratio, enhancing its capital operation capabilities[86]. - The company reported a significant rise in asset impairment losses, increasing by 136.02% to ¥331.47 million, indicating higher provisions for production-related asset impairments[88]. - The cash flow from financing activities surged by 675.32% to ¥12.14 billion, attributed to cash received from a private placement of shares[88]. - The company has a stable profit distribution policy, ensuring that cash dividends over the last three years account for at least 30% of the average distributable profits[118]. Corporate Governance and Compliance - The company has established internal compliance and risk management policies to ensure adherence to applicable laws and regulations in both mainland China and Hong Kong[181]. - The company has not issued, repurchased, sold, or redeemed any bonds during the fiscal year ending December 31, 2022[183]. - The company confirmed that all related party transactions were conducted under normal commercial terms and did not exceed the approved limits[179]. - The company has implemented a performance evaluation mechanism based on core, operational, and constraint indicators to determine compensation for directors and senior management[192]. - The company has a non-competition agreement with its major shareholders, ensuring they do not engage in competing businesses or investments[196]. Employee and Talent Management - The company has established a differentiated compensation system for various roles, including management, marketing, R&D, and production, to enhance employee motivation and performance[192]. - In 2022, the company organized 26 training projects, 62 classes, and 24 forums, with a total of 12,802 participants in its empowerment training programs[195]. - The company has developed a comprehensive training system to enhance leadership and professional capabilities, including international management training[195]. - The company has a mechanism in place to ensure that employee income growth is linked to company performance, allowing employees to share in the company's success[192]. Shareholder Information - The top ten shareholders held a total of 1,329,695,237 shares, representing 40.52% of the total issued shares[130]. - Shanghai Pharmaceuticals Group holds 716,516,039 shares, accounting for 19.38% of the total issued shares[130]. - The company plans to distribute a cash dividend of RMB 6.10 per 10 shares, totaling RMB 2,255,503,164.92, which accounts for 40.15% of the net profit attributable to shareholders for the year[115]. - The company has granted a total of 25,600,000 stock options to 210 incentive targets as of December 19, 2019, which was later adjusted to 23,258,120 options for 190 targets due to personnel changes[134][136]. Risks and Challenges - The company faces risks related to geopolitical and international economic conditions, which may impact international trade and investment in the short term[114]. - The company will closely monitor industry changes and increase R&D investment to mitigate risks associated with project development and clinical trial outcomes[114]. - The domestic pharmaceutical industry is witnessing a shift towards innovation-driven development, with policies promoting the accessibility of innovative products[106].

Financial Performance - In Q1 2023, the company achieved revenue of 66.226 billion RMB, a year-on-year increase of 16.39%[9] - The pharmaceutical manufacturing segment generated sales revenue of 7.801 billion RMB, up 12.60% year-on-year, with 60 key products contributing 4.604 billion RMB, a 13.84% increase[9] - The pharmaceutical commercial segment reported sales revenue of 58.425 billion RMB, reflecting a year-on-year growth of 16.92%[9] - The net profit attributable to shareholders was 1.518 billion RMB, representing a year-on-year increase of 21.31%, with the industrial business contributing 0.708 billion RMB and the commercial business contributing 0.861 billion RMB[9] - The company's revenue for the first quarter of 2023 was approximately ¥66.23 billion, representing a year-on-year increase of 16.39%[19] - The net profit attributable to shareholders was approximately ¥1.52 billion, reflecting a year-on-year growth of 21.31%[19] - Total operating revenue for Q1 2023 reached ¥66.23 billion, a 16.5% increase from ¥56.90 billion in Q1 2022[32] - Net profit for Q1 2023 was ¥1.95 billion, representing a 27.5% increase compared to ¥1.53 billion in Q1 2022[34] Research and Development - R&D investment reached 0.547 billion RMB, a 15.80% increase year-on-year, with R&D expenses at 0.541 billion RMB, up 20.82%[9] - The company has 64 new drug candidates in clinical research, including 52 innovative drugs and 12 improved new drugs[11] - The first self-developed new drug, I001, has completed Phase III clinical trials for hypertension, showing positive results[11] - The company has submitted a pre-NDA application for the new drug I008-A, targeting chronic immune disorders, which is expected to fill a clinical gap[12] - Research and development expenses for Q1 2023 were ¥540.69 million, an increase of 20.8% from ¥447.50 million in Q1 2022[33] - Research and development expenses increased to CNY 124,552,189.62 in Q1 2023 from CNY 106,026,867.46 in Q1 2022, reflecting a growth of about 17.5%[42] Market Expansion - The company is expanding its traditional Chinese medicine segment, leveraging historical brands and products with significant cultural heritage[13] - The company aims to enhance its market position in the Chinese medicine sector, supported by national policies promoting the industry[13] - The company has expanded its international presence by entering the Philippine market, with the approval of four specifications of Rosuvastatin Calcium Tablets[16] - The company plans to continue focusing on the Southeast Asian market to enhance its global commercial footprint[16] Assets and Liabilities - The total assets at the end of the reporting period were approximately ¥206.04 billion, an increase of 3.99% compared to the end of the previous year[19] - As of March 31, 2023, the total assets of the company amounted to RMB 206,035,799,280.43, an increase from RMB 198,134,901,498.95 as of December 31, 2022, reflecting a growth of approximately 4.8%[28] - The company's current assets totaled RMB 157,170,379,297.84, up from RMB 149,512,870,619.79, indicating an increase of about 5.5%[28] - Total liabilities as of Q1 2023 amounted to ¥126.15 billion, an increase from ¥120.13 billion in the previous year[30] - The total liabilities increased to CNY 24.60 billion from CNY 22.29 billion at the end of 2022[41] Cash Flow - The cash flow from operating activities was negative at approximately -¥2.62 billion, indicating increased cash outflows for purchases and services[19] - In Q1 2023, the company reported cash inflows from operating activities of approximately CNY 64.27 billion, an increase of 15.5% compared to CNY 55.91 billion in Q1 2022[35] - The net cash outflow from operating activities was CNY -2.62 billion, slightly worse than the CNY -2.49 billion reported in the same period last year[36] - The company generated CNY 9.56 billion from investment activities, a significant increase from CNY 180.58 million in Q1 2022[36] - The net cash outflow from investment activities was CNY -2.11 billion, compared to CNY -631.10 million in the previous year[36] - Cash inflows from financing activities totaled CNY 26.49 billion, down from CNY 34.75 billion in Q1 2022[36] - The net cash inflow from financing activities was CNY 4.31 billion, a decrease from CNY 17.59 billion in the same quarter last year[36] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 78,061[24] - The company reported a total of 3,698,499,159 shares issued, comprising 2,779,426,455 A-shares and 919,072,704 H-shares[26] Financial Ratios - The weighted average return on equity decreased to 2.24%, down by 0.26 percentage points from the previous year[19] - Total equity for Q1 2023 was ¥79.88 billion, up from ¥78.00 billion in Q1 2022[30] - The company's long-term borrowings increased to ¥8.60 billion in Q1 2023 from ¥6.26 billion in Q1 2022[30] - The company's financial expenses decreased to CNY 57,188,926.70 in Q1 2023 from CNY 80,460,137.77 in Q1 2022, a reduction of approximately 29%[42]

Financial Performance - The company achieved operating revenue of RMB 66.226 billion in Q1 2023, representing a year-on-year growth of 16.39%[7] - The net profit attributable to shareholders was RMB 1.518 billion, reflecting a year-on-year growth of 21.31%[7] - The pharmaceutical commercial segment generated RMB 58.425 billion in sales, marking a year-on-year growth of 16.92%[7] - The sales of the innovative drug segment increased by approximately 28% year-on-year, with 7 new imported products introduced[13] - Net profit for Q1 2023 reached approximately ¥1.95 billion, up 27.5% from ¥1.53 billion in Q1 2022[27] - Total comprehensive income for Q1 2023 was approximately ¥1.92 billion, compared to ¥1.49 billion in Q1 2022, reflecting a growth of 28.7%[29] - Basic earnings per share for Q1 2023 were ¥0.41, a decrease from ¥0.44 in Q1 2022[29] - The company reported a basic earnings per share of ¥0.41, down by 6.75% year-on-year[14] Research and Development - R&D investment totaled RMB 547 million, an increase of 15.80% year-on-year, with R&D expenses at RMB 541 million, up 20.82%[7] - The company has 64 new drug candidates in clinical research, including 52 innovative drugs and 12 improved new drugs[9] - The first self-developed 1.1 class new drug, I001, has completed Phase III clinical trials for hypertension, achieving primary endpoint success[10] - The company submitted a pre-NDA application for I008-A, targeting chronic immune disorders related to HIV, aiming to fill clinical gaps[10] - R&D expenses increased to ¥540.69 million in Q1 2023, compared to ¥447.50 million in Q1 2022, indicating a focus on innovation[26] - Research and development expenses increased to ¥124,552,189.62 in Q1 2023 from ¥106,026,867.46 in Q1 2022, reflecting a growth of approximately 17.5%[36] Financial Position - The total assets at the end of the reporting period were ¥206,035,799,280.43, a 3.99% increase from the previous year[15] - The company's total assets reached ¥206.04 billion as of March 31, 2023, up from ¥198.13 billion at the end of 2022[25] - The equity attributable to shareholders increased to ¥68.57 billion as of March 31, 2023, from ¥67.06 billion at the end of 2022, reflecting growth in shareholder value[25] - Total liabilities increased to ¥126.15 billion as of March 31, 2023, compared to ¥120.13 billion at the end of 2022, indicating higher financial obligations[25] - The company's current assets totaled RMB 157,170,379,297.84 as of March 31, 2023, compared to RMB 149,512,870,619.79 as of December 31, 2022, reflecting an increase[22] Cash Flow - The net cash flow from operating activities was negative at -¥2,623,322,412.29, indicating a significant cash outflow[14] - Cash inflow from operating activities in Q1 2023 was approximately ¥64.27 billion, an increase from ¥55.91 billion in Q1 2022[30] - Cash outflow from operating activities totaled approximately ¥66.90 billion in Q1 2023, compared to ¥58.40 billion in Q1 2022[31] - The company reported cash inflow from investment activities of approximately ¥9.56 billion in Q1 2023, significantly higher than ¥180.58 million in Q1 2022[31] - Cash outflow from investment activities in Q1 2023 was approximately ¥11.67 billion, compared to ¥811.68 million in Q1 2022[31] - The total cash and cash equivalents at the end of Q1 2023 amounted to ¥24,104,731,465.82, down from ¥34,611,200,668.81 at the end of 2022, representing a decrease of 30.5%[32] Shareholder Information - The total number of common shareholders at the end of the reporting period was 78,061[20] - The top three shareholders held the following shares: Shanghai Pharmaceuticals Group (716,516,039 shares, 19.373%), HKSCC Nominees Limited (689,221,624 shares, 18.635%), and Yunnan Baiyao (665,626,796 shares, 17.997%)[19] - The total number of issued A-shares was 2,779,426,455 and H-shares was 919,072,704, totaling 3,698,499,159 shares[20] Market Expansion - The company is focusing on the traditional Chinese medicine sector, with plans to enhance the value of its eight core TCM enterprises[11] - The company plans to continue deepening its focus on the Southeast Asian market and expanding its global commercial footprint[13] - The company expanded its international presence by launching four specifications of Rosuvastatin Calcium Tablets in the Philippines[13] Investment Performance - The profit contribution from major equity investments was RMB 177 million, down 15.12% year-on-year[7] - The company reported a net investment income of ¥155.16 million in Q1 2023, down from ¥179.73 million in Q1 2022, indicating fluctuations in investment performance[26] - Investment income for Q1 2023 was reported at ¥225,801,358.48, compared to ¥192,498,159.54 in Q1 2022, showing an increase of approximately 17.3%[36]

证券代码：601607 证券简称：上海医药 公告编号：临 2023-040 上海医药集团股份有限公司 关于召开 2023 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： （网址：http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心音频直播结合网络互动 投资者可于 2023 年 04 月 23 日(星期天) 至 04 月 26 日(星期三)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 boardoffice@sphchina.com 进行提问。公司将在说明会上对投资者普遍关注的 问题进行回答。 上海医药集团股份有限公司（以下简称"公司"）将于 2023 年 4 月 26 日晚 发布《公司 2023 年第一季度报告》。为便于广大投资者更全面深入地了解公司 2023 年第一季度的经营成果和财务状况，公司计划于 2023 年 04 月 27 日下午 13:00-14:00 举行 2023 年第一季度业绩说明会，就投资者关 ...